中国临床药理学杂志
中國臨床藥理學雜誌
중국림상약이학잡지
The Chinese Journal of Clinical Pharmacology
2015年
19期
1928-1930
,共3页
多囊卵巢综合征%来曲唑%不同剂量%促排卵治疗
多囊卵巢綜閤徵%來麯唑%不同劑量%促排卵治療
다낭란소종합정%래곡서%불동제량%촉배란치료
polycystic ovarian syndrome%letrozole%different dosage%promoting ovulation
目的 评价不同剂量来曲唑用于多囊卵巢综合征患者促排卵的临床疗效和安全性. 方法 将88例拟进行促排卵治疗的多囊卵巢综合征患者随机分为对照组42例和试验组46例. 2组患者均于月经来潮第3天起开始服药,对照组予以口服来曲唑2.5 mg? d-1 ,连续5 d;试验组予以口服来曲唑5 mg? d-1 ,连续5 d. 月经周期第10天,开始进行阴道超声检查,并监测卵泡发育情况,比较2组患者的排卵率和周期妊娠率以及不良反应发生率. 结果 对照组有33例排卵,排卵率78.57%,临床妊娠2例,周期妊娠率为6.1%( 2/33 ) ,试验组有34例排卵,排卵率为73.91%,临床妊娠9例,周期妊娠率为26.5%(9/34),其中试验组周期妊娠率显著高于对照组( P<0.05 ). 对照组与试验组成熟卵泡数分别为(1.0 ±0.4)个和(1.5 ±0.6)个,试验组显著高于对照组(P<0.05). 对照组用药期间发生关节痛2例、恶心1例,试验组发生关节痛1例、恶心1例,2组患者不良反应发生率比较差异无统计学意义(P>0.05).结论 5.0mg?d-1来曲唑与2.5 mg? d-1来曲唑相比可显著提高多囊卵巢综合征患者的周期妊娠率,同时不增加不良反应风险.
目的 評價不同劑量來麯唑用于多囊卵巢綜閤徵患者促排卵的臨床療效和安全性. 方法 將88例擬進行促排卵治療的多囊卵巢綜閤徵患者隨機分為對照組42例和試驗組46例. 2組患者均于月經來潮第3天起開始服藥,對照組予以口服來麯唑2.5 mg? d-1 ,連續5 d;試驗組予以口服來麯唑5 mg? d-1 ,連續5 d. 月經週期第10天,開始進行陰道超聲檢查,併鑑測卵泡髮育情況,比較2組患者的排卵率和週期妊娠率以及不良反應髮生率. 結果 對照組有33例排卵,排卵率78.57%,臨床妊娠2例,週期妊娠率為6.1%( 2/33 ) ,試驗組有34例排卵,排卵率為73.91%,臨床妊娠9例,週期妊娠率為26.5%(9/34),其中試驗組週期妊娠率顯著高于對照組( P<0.05 ). 對照組與試驗組成熟卵泡數分彆為(1.0 ±0.4)箇和(1.5 ±0.6)箇,試驗組顯著高于對照組(P<0.05). 對照組用藥期間髮生關節痛2例、噁心1例,試驗組髮生關節痛1例、噁心1例,2組患者不良反應髮生率比較差異無統計學意義(P>0.05).結論 5.0mg?d-1來麯唑與2.5 mg? d-1來麯唑相比可顯著提高多囊卵巢綜閤徵患者的週期妊娠率,同時不增加不良反應風險.
목적 평개불동제량래곡서용우다낭란소종합정환자촉배란적림상료효화안전성. 방법 장88례의진행촉배란치료적다낭란소종합정환자수궤분위대조조42례화시험조46례. 2조환자균우월경래조제3천기개시복약,대조조여이구복래곡서2.5 mg? d-1 ,련속5 d;시험조여이구복래곡서5 mg? d-1 ,련속5 d. 월경주기제10천,개시진행음도초성검사,병감측란포발육정황,비교2조환자적배란솔화주기임신솔이급불량반응발생솔. 결과 대조조유33례배란,배란솔78.57%,림상임신2례,주기임신솔위6.1%( 2/33 ) ,시험조유34례배란,배란솔위73.91%,림상임신9례,주기임신솔위26.5%(9/34),기중시험조주기임신솔현저고우대조조( P<0.05 ). 대조조여시험조성숙란포수분별위(1.0 ±0.4)개화(1.5 ±0.6)개,시험조현저고우대조조(P<0.05). 대조조용약기간발생관절통2례、악심1례,시험조발생관절통1례、악심1례,2조환자불량반응발생솔비교차이무통계학의의(P>0.05).결론 5.0mg?d-1래곡서여2.5 mg? d-1래곡서상비가현저제고다낭란소종합정환자적주기임신솔,동시불증가불량반응풍험.
Objective To evaluate the promoting ovulation effects of different dosage of letrozole in the treatment of patients with polycystic ovarian syndrome ( POS) .Methods Eighty -eight patients with POS were randomly divided into control group ( n=42 ) and treatment group (n=46).Patients in two groups began to take drug in the third day of menstruation.Patients in the control group were treated with letrozole 2.5 mg? d-1 for 5 days.Patients in the treatment group were treated with letrozole 5.0 mg? d-1 for 5 days.Ultrasound scanning was performed to monitor the follicle development in 10th after menstrual cycle.The ovula-tion, pregnancy and incidence rate were compared .Results The ovula-tion rate were 78.57% and 73.91% in the control and treatment group respectively , with no significant difference ( P>0.05 ) .The pregnancy rate in the treatment group was significantly higher than in the control group ( P <0.05 ) . The maturity ovary were ( 1.0 ±0.4 ) and (1.5 ±0.6 ) in the control and treatment group which indicated the treatment group was much higher ( P <0.05 ) . The adverse drug reactions such as arthralgia and nausea were not significantly different between the two groups (P>0.05).Conclusion Compared with 2.5 mg? d -1 letrozole, 5.0 mg? d-1 letrozole can improve the pregnancy rate but with the increasing of adverse drug reactions in patients with POS .
